KRTX News and Press, Karuna Therapeutics Inc. From 08/16/23

2023-08-16 17:08:23 ET Summary Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizophrenia and Alzheimer's-related psychosis. Karuna Therapeutics faced a net loss of $103.2M in Q2 2023...

2023-08-05 05:02:06 ET Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Conference Call Aug 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations William Meury - President and Chief Executive Officer Troy Ignelzi - Chief Fi...

2023-08-03 07:30:27 ET Karuna Therapeutics press release ( NASDAQ: KRTX ): Q2 GAAP EPS of -$2.75 beats by $0.09 . Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Office...

On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3 ADEPT-3 open label extension trial in the third quarter of 2023, and on track ...

Jonathan Rosin appointed to Chief Human Resources Officer Jason Brown promoted to Chief Financial Officer Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

2023-08-02 13:11:10 ET Karuna Therapeutics ( NASDAQ: KRTX ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$2.78 (-28.1% Y/Y) and the consensus Revenue Estimate is $0.45M (-91.5% Y/Y). Over the l...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, August 3, 20...

2023-06-06 07:35:31 ET Summary Karuna Therapeutics' KarXT for schizophrenia is a much-hyped asset. However, there are small signs of trouble - probably nothing, but they are there. The current price seems to have priced in all these major pros and minor cons. Karuna ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Goldman Sachs 44 th Annual Global Heal...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating Ka...